Literature DB >> 12459682

Effects of delayed administration of low-dose lidocaine on transient focal cerebral ischemia in rats.

Baiping Lei1, Susanna Popp, Christine Capuano-Waters, James E Cottrell, Ira S Kass.   

Abstract

BACKGROUND: The authors' previous study demonstrated that a clinical antiarrhythmic dose of lidocaine, when given before ischemia, is neuroprotective in a rat model of transient focal cerebral ischemia. In this study, the authors investigated whether the administration of this dose of lidocaine, when delayed until 45 min after the onset of ischemia, also reduces ischemic brain injury.
METHODS: Lidocaine was administered as an intravenous bolus (1.5 mg/kg) followed by an intravenous infusion (2 mg. kg(-1).h(-1)) for 165 min, beginning 45 min after the onset of a 90-min period of transient focal cerebral ischemia. Control animals were given the same volume of saline. Focal cerebral ischemia was induced by occluding the right middle cerebral artery using an intraluminal suture. Neurologic outcome and body weight loss were quantified 7 days later. The brain was fixed 7 days after ischemia and brain sections were stained with hematoxylin and eosin for assessment of infarct size and the number of intact neurons. In separate experiments, local cerebral blood flow and the electroencephalogram were measured during ischemia and 180 min into the reperfusion period. Infarct size was assessed after 24 h.
RESULTS: Infarct size, at either 24 h or 7 days after ischemia, was not significantly reduced in the lidocaine group. However, the number of intact neurons was significantly increased in both the ischemic penumbra and core of the lidocaine group 7 days after ischemia, compared with the vehicle group. Rats treated with lidocaine demonstrated better neurologic outcome and less weight loss (P < 0.05). Lidocaine treatment had no significant influence on local cerebral blood flow and electroencephalogram during ischemia and reperfusion.
CONCLUSIONS: Administration of a clinical antiarrhythmic dose of lidocaine, beginning 45 min after the onset of ischemia, reduces ischemic brain injury after transient focal cerebral ischemia in the rat. This indicates that delayed administration of neuroprotective agents may reduce brain damage resulting from ischemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12459682     DOI: 10.1097/00000542-200212000-00028

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  7 in total

Review 1.  ["Alternative" effects of local anesthetic agents].

Authors:  S Pecher; B W Böttiger; B Graf; M W Hollmann
Journal:  Anaesthesist       Date:  2004-04       Impact factor: 1.041

2.  The use of alfaxalone and remifentanil total intravenous anesthesia in a dog undergoing a craniectomy for tumor resection.

Authors:  Leon N Warne; Thierry Beths; Sandra Fogal; Sébastien H Bauquier
Journal:  Can Vet J       Date:  2014-11       Impact factor: 1.008

3.  Delayed treatment with lidocaine reduces mouse microglial cell injury and cytokine production after stimulation with lipopolysaccharide and interferon γ.

Authors:  Hae-Jeong Jeong; Daowei Lin; Liaoliao Li; Zhiyi Zuo
Journal:  Anesth Analg       Date:  2012-01-16       Impact factor: 5.108

Review 4.  Neuroprotective effect of lidocaine: is there clinical potential?

Authors:  Tiandong Leng; Xiuren Gao; James P Dilger; Jun Lin
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2016-04-25

Review 5.  Lignocaine: neuro-protective or wishful thinking?

Authors:  Simon J Mitchell; Alan F Merry
Journal:  J Extra Corpor Technol       Date:  2009-03

6.  Total intravenous anaesthesia in a goat undergoing craniectomy.

Authors:  Verónica Vieitez; Ignacio Álvarez Gómez de Segura; Víctor López Rámis; Massimo Santella; Luis Javier Ezquerra
Journal:  BMC Vet Res       Date:  2017-09-15       Impact factor: 2.741

7.  Lidocaine attenuates hypoxia/reoxygenation‑induced inflammation, apoptosis and ferroptosis in lung epithelial cells by regulating the p38 MAPK pathway.

Authors:  Xiaojun Ma; Weihua Yan; Na He
Journal:  Mol Med Rep       Date:  2022-03-04       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.